Soteri Skin, founded with a mission to provide long-lasting relief for chronic skin conditions like eczema, offers direct-to-consumer (D2C) skincare solutions. Their core product features the patented pH/LOCK™ technology, which maintains the skin at a therapeutic pH for over 12 hours, addressing both symptoms and root causes of eczema. Soteri Skin aims to serve the 30 million Americans suffering from eczema by providing steroid-free, clinically tested treatments that restore the skin's acid mantle and correct pH imbalances.
Notable figures associated with Soteri Skin include its founders and key investors who have supported its innovative approach to skincare. The company has achieved significant milestones, including being the only non-prescription product clinically proven to offer long-term eczema relief. Soteri Skin's impact is evident in its growing customer base and positive reviews, establishing it as a trusted name in the skincare market for chronic conditions.
